Up-regulation of microRNA-125b induced by 5-fluorouracil (5-FU) treatment inhibits cell growth and proliferation in pancreatic cancer cells

Abstract

MicroRNAs (miRNAs) are a class of small non-coding RNAs that play regulatory roles in protein synthesis by repressing translation or cleaving RNA transcripts. Their aberrant expression has been shown to be involved in human diseases, including cancer. The functional importance of miRNAs is evidenced by many biological processes in which they are implicated, including developmental timing, cell proliferation, apoptosis, metabolism, cell differentiation and morphogenesis. However, little is known about the roles of miRNAs in 5-Fluorouracil (5-FU) resistance and metabolism pathway in pancreatic cancer cells. To address this enigma, miRNA profiles that correlate with 5-FU treatments are defined using miRNA microarray, and comparison of miRNA profiles reveals specific differences between untreated and 5-FU treated pancreatic cancer cells. A subset of miRNAs is being upregulated in 5-FU treated pancreatic cancer cells, with the most significantly upregulated miRNAs being miR-125b, miR-181a, miR-181b, miR-181d, miR-27a, miR-222, miR-30a-5pre and miR-495. Transient transfection of the Pre-miRTM miRNA precursor molecules for miR-125b showed that it inhibited cell proliferation. Expression plasmids of miR-125b were constructed and transfected into human pancreatic cancer cell line PANC-1. PANC-1 miR-125b transfected stable clones showed decreased cell growth and proliferation. Our study suggested that miR-125b may act as a tumor suppressor and present a novel strategy for anticancer therapy.

Keywords: microRNA microarray, pancreatic cancer, microRNA-125b, cell growth, cell proliferation

Abbreviations: 5-FU, 5-fluorouracil; miRNA, microRNA; FBS, fetal bovine serum; DMEM, dulbecco’s modified eagle’s medium

Introduction

Pancreatic cancer is one of the most frequently reported gastrointestinal tumors and has been reported to have a 5-year survival rate of <5%. It is most commonly diagnosed at an advanced stage and the most frequently administered chemotherapeutic compound for patients with advanced disease has been 5-Fluorouracil (5-FU).1 5-FU alone remains one of the standard treatments in advanced pancreatic cancer. The well-known mechanism of the anti-tumor effects of 5-FU is to inhibit DNA and RNA synthesis.1 In addition, cell resistance to cytotoxic agents and radiation are two other factors contributing to the poor prognosis of pancreatic cancer.2

Recently it has been demonstrated that miRNAs may provide an additional post-transcriptional mechanism by which protein expression can be negatively regulated by either translational repression or mRNA degradation. MiRNAs are produced endogenously in mammalian cells approximately 60-nt long pre-miRNA hairpin intermediates. They are further processed to around 22-nt miRNA duplexes which regulate the stability or translational efficiency of target mRNAs by base-pairing to complementary sites on the targets.3 The functional importance of miRNAs is evidenced by many biological processes in which they are involved, including developmental timing, cell proliferation, apoptosis, metabolism, cell differentiation and morphogenesis.4,5 It has been shown that miRNAs are aberrantly expressed or mutated in cancer, suggesting that they may play a role as a novel class of oncogenes or tumor suppressor genes.6,7 However, the roles of miRNAs in 5-FU resistance and metabolism pathway remain largely unknown in pancreatic cancer cells. Our study was concentrated on defining miRNA profiles correlated with 5-FU treatment in pancreatic cancer. By comparing miRNA profiles of 5-FU treated and non-treated pancreatic cancer cells, we were able to identify potential upregulated miRNAs as a result of 5-FU treatment in pancreatic cancer cells. The functional study further confirmed miR-125b maybe served as a tumor suppressor gene.

Materials and methods

Cell culture and 5-FU treatment

Human pancreatic cell lines PANC-1 and Panc-10.05 were purchased from American Type Culture Collection (ATCC, Manassas, VA). PANC-1 was maintained in Dulbecco’s Modified Eagle’s medium (DMEM, HyClone, Logan, UT) supplemented with 10% fetal bovine serum (FBS) (Sigma, St. Louis, MO, USA), 100μg/ml streptomycin and 100μg/ml penicillin (pH 7.2-7.4). Panc-10.05 was maintained in RPMI-1640 medium (HyClone, Logan, UT) supplemented with 15% fetal FBS 100μg/ml streptomycin and 100μg/ml penicillin (pH 7.2-7.4). MTT assay was performed to determine the 5-FU (Sigma, St. Louis, MO, USA) concentration causing 50% growth inhibition (IC50) for PANC-1 and Panc-10.05 after 72 hours of 5-FU treatment compared with the control groups which have no treatment.

RNA extraction

Total RNAs were isolated using mirVanaTM miRNA Isolation kit.
Kit (Ambion, Austin, Texas) according to the instructions of the manufacturer. The quality of the RNA was assessed by 15% denaturing polyacrylamide gel electrophoresis and spectrophotometry (Eppendorf BioPhotometer, Eppendorf, Hamburg, Germany).

MicroRNA microarray

MiRNA microarray analysis was performed by LC Sciences (http://www.lcsiences.com/; Houston, TX). In brief, poly-A tails were added to the RNA sequences at the 3’-ends using a poly (A) polymerase, and nucleotide tags were then ligated to the poly-A tails. For each dual-sample experiment, two-sets of RNA sequences were added with tags of two different sequences. The tagged RNA sequences were then hybridized to the miRNA microarray chip (Atactic μ ParaFlo™ micro fluidics chip, LC Sciences, Houston, Texas) containing 328 human mature miRNA transcripts listed in Sanger miRBase Release 8.0 (http://www.sanger.ac.uk/Software/Rfam/mirna/). The probe sequences are available upon request. The labeling reaction was carried out during the second hybridization reaction using tag-specific dendraimer Cy3 and Cy5 dyes. Total RNAs from untreated cells and cells treated with 5-FU were labeled with Cy3 and Cy5, respectively. The human miRNA chip includes nine repeats for each miRNA. Multiple control probes were included in each chip, which were used for quality control of chip production, sample labeling and assay conditions. Hybridization signals were detected by Axon Genepix 4000B Microarray Scanner (Molecular Devices, Sunnyvale, CA) and saved as TIFF files. Numerical intensities were extracted for control, background, and miRNA probes and converted into Microsoft Excel spreadsheets.

Data analysis

The data were corrected by subtracting the background and normalizing to the statistical median of all detectable transcripts. Background was calculated from the median of 5% to 25% of the lowest-intensity cells. The data normalization balances the intensities of Cy3- and Cy5-labeled transcripts so that differential expression ratios can be correctly calculated. Statistical comparisons were performed by ANOVA (Analysis of Variance) using the Benjamini and Hochberg correction for false-positive reductions. Differentially detected signals were generally accepted as true when the ratio of the P value was less than 0.01. Clustering analysis was made with a hierarchical method and visualized using the TIGR MeV microarray program.

Real-time RT-PCR

Expression of miRNAs was measured using mirVanaTM qRT-PCR miRNA Detection Kit and mirVana™ qRT-PCR Primer Sets (Ambion, Austin, Texas) according to the instructions of the manufacturer. Briefly, cDNA was generated after reverse transcription of 20ng RNA. The PCR reaction consisting of appropriate number of cycles (95°C for 15 s, 60°C for 30 s) was performed using a iCycler (Bio-Rad, Hercules, CA). After an initial denaturation step (95°C for 30 s), the real-time PCR products were separated on a 3.5% agarose gel and visualized with ethidium bromide on the ChemiImager Imaging System 5500 (Alpha Innotech, San Leandro, CA) after an initial denaturation step (95°C for 15 s, 60°C for 30 s) was performed using an iCycler (Bio-Rad, Hercules, CA). A cycle number of 2000 was used as a control.

Northern blotting

Northern blot analysis was performed as previously described.8 Briefly, 10 µg of RNA from each sample was separated on 15% polyacrylamide gel with 8 M urea and transferred onto Bright Star®-Plus positively charged nylon membrane (Ambion, Austin, Texas) using semi-dry transfer apparatus (Bio-Rad, Hercules, CA). Blots were prehydrized at 65°C for 1hour in prehybridization buffer (200mM NaHPO4, pH7.0, 5% SDS) and subjected to hybridization with 32P-labeled miR-125b, -181a, -181b, -27a or -222 probe overnight. 32P-labeled U6 probe was used as an internal control. Following hybridization, membranes were washed twice for 10min each at 25°C using low-strengthency buffer (25mM NaHPO4, pH7.5, 5% SDS, 3× SSC), and once for 10minutes at 42°C using high-strengency buffer (1% SDS, 1× SSC). The blots were exposed to X-ray film for 72-96hours (PIERCE, Rockford, IL). The oligonucleotides used as probes are the complementary sequences of the mature miRNA obtained from miR Registry (http://www.sanger.ac.uk/Software/Rfam/mirna/). miR-125b: 5'-acaaagttagtgctcaggga-3'; miR-181a: 5’-actcaccgacagcgttgaatgtt-3'; miR-27a: 5’-gggagcaactccatgttgaggt-3'; miR-181b: 5’-cccaacagcaaatgtatggt-3'; miR-27a: 5’-gggagcaactccatgttgaggt-3'; miR-222: 5’-ggagcc acttggctcttctgatg-3'. An oligonucleotide complementary to the U6 RNA (5’-cgagcggccatgtatactctctctgatgtg-3') was used as control to normalize expression levels.

Transient transfection

The Pre-miRTM miRNA Precursor Molecules for miR-125b were purchased from Ambion (Austin, TX). Transfection was performed using LipofectamineTM 2000 (Invitrogen, Carlsbad, CA) according to the instructions of the manual. Briefly, PANC-1 and Panc10.05 cells were seeded on 6-well plates one day before transfection. Next day Pre-miRTM miRNA Precursor Molecules were diluted in 250µl of Opti-MEM, and mixed gently. Meanwhile, 10µl LipofectamineTM 2000 was diluted in 250µl of Opti-MEM, and mixed gently. After incubation of 20minutes at room temperature, the diluted Pre-miRTM miRNA Precursor Molecules were diluted with diluted LipofectamineTM 2000, and mixed gently for incubation of 5minutes at room temperature. The complexes were added to each well containing cells and medium. Cells were incubated at 37°C in CO2 for 24-hours prior to testing.

Preparation of constructs and stable transfection

A single-stranded DNA oligos was designed for hsa-miR-125b according to the instructions of the BLOCK-iT Pol II miRNA Expression Vector kit (Invitrogen, Carlsbad, CA). The top and bottom strand oligos were annealed to generate a double-stranded oligo suitable for cloning into the pcDNA6.2-GW/EmGFP-miR vector (Invitrogen, Carlsbad, CA). The pcDNA6.2-GW/EmGFP-miR-neg control plasmid contains an insert between bases 1519 and 1578 that can form a hairpin structure just as a regular pre-miRNA, but is designed not to target any known vertebrate gene. TOP10 competent E. coli was transformed with the expression plasmid. Plasmid DNA was isolated and sequenced by automated sequencing to confirm the sequence. Stable transfection was performed in both PANC-1 and Pac-10.05 cells. Cells were transfected with either the expression plasmid or the control vector using LipofectamineTM 2000 (Invitrogen, Carlsbad, CA). After blasticidin (3µg/ml, Invitrogen, Carlsbad, CA) screening, the stable clones were identified by semi-quantitative RT-PCR and Northern blot.

MTT assay

Cell proliferation rate was determined by MTT assay. Parent cells and transfectants with miR-125b expression plasmid as well as control vector clones were digested with trypsin and inoculated in 96-well plates at a concentration of 1×104 cells/well after counting. Cells were incubated at 37°C in a humidified incubator containing 5% CO2. Cell viability was examined every day for 7 days. According to manufacture instructions, 30µl of MTT (5mg/ml, dissolved in...
Up-regulation of miR-125b induced by 5-fluorouracil (5-FU) treatment inhibits cell growth and proliferation in pancreatic cancer cells

Results

Determination of IC_{50} for PANC-1 and Panc-10.05

IC_{50} is necessary for this study. Therefore, both pancreatic cell lines PANC-1 and Panc 10.05 were treated for 72 hours with various concentrations of 5-FU. MTT assay results indicated that IC_{50} for PANC-1 and Panc-10.05 are 75 µg/ml and 200 µg/ml, respectively. These concentrations were the guideline for the 5-FU treatment in this study.

miRNA profiles correlated to 5-FU induced cell toxicity

In order to examine the miRNA profiles correlated with 5-FU induced cell toxicity towards pancreatic cancer cells, total RNAs from 5-FU treated and non-treated pancreatic cancer cells were isolated and miRNA microarray analyses were performed after assessing the quality of total RNA. Correlation analysis was performed to ensure the quality of miRNA microarray analysis. By correlating the results from 2 chips, the fluorescence labeling, handling, and system related biases can be eliminated and therefore the expression pattern and level are reliable to the true biological differences. A list of differentially expressed miRNAs (at P < 0.01) between 5-FU treated and untreated cells was identified and presented in Table 1. We further selected miR-125b, miR-181a, miR-181b, miR-27a and miR-222 based on the differential expression ratio (ratio > 1.5) and availability of the primer set for validation.

Table 1 Differentially expressed miRNAs between 5-FU treated and untreated cells

| miRNA candidates | ± ratio | Chromosomal location |
|------------------|---------|----------------------|
| hsa-let-7g       | 1.5     | 3p21.2               |
| hsa-let-7i       | 1.42    | 12q14.1              |
| hsa-mir-100      | 2.13    | 11q24.1              |
| hsa-mir-103-1    | 1.67    | 5q34                 |
| hsa-mir-103-2    | 1.67    | 20p13                |
| hsa-mir-107      | 1.69    | 10q23.31             |
| hsa-mir-125a     | 1.82    | 19q13.41             |
| hsa-mir-125b-1   | 4.02    | 1q21.1               |
| hsa-mir-125b-1   | 4.02    | 1q21.1               |
| hsa-mir-181a-1   | 2.31    | 1q31.3               |
| hsa-mir-181a-2   | 2.31    | 9q33.3               |
| hsa-mir-181b-1   | 2.72    | 1q31.3               |
| hsa-mir-181b-2   | 2.72    | 9q33.3               |
| hsa-mir-181d     | 4.33    | 19p13.12             |
| hsa-mir-20a      | 1.43    | 13q31.3              |
| hsa-mir-221      | 1.44    | Xp11.3               |
| hsa-mir-222      | 1.63    | Xp11.3               |
| hsa-mir-27a      | 2.38    | 19p13.12             |
| hsa-mir-29a      | 1.52    | 7q32.3               |
| hsa-mir-30a-5pre | 1.78    | 6q13                 |

Statistical analysis

Results were shown as mean±SD. Student’s t test was used for comparison unless particular test was notified. P < 0.05 was considered statistically significant.

Citation: Liu Y, Liu Z, Xia Z, et al. Up-regulation of miR-125b induced by 5-fluorouracil (5-FU) treatment inhibits cell growth and proliferation in pancreatic cancer cells. MOJ Cell Sci Rep. 2016;3(1):30-37. DOI: 10.15406/mojcsr.2016.03.00048
Up-regulation of miRNA-125b induced by 5-fluorouracil (5-FU) treatment inhibits cell growth and proliferation in pancreatic cancer cells

Table Continued....

| miRNA candidates | ± ratio | Chromosomal location |
|------------------|---------|---------------------|
| **Up-regulated** |         |                     |
| hsa-mir-30c-1    | 1.25    | 1p34.2              |
| hsa-mir-30c-2    | 1.25    | 1q13               |
| hsa-mir-31       | 1.64    | 1p21.3             |
| hsa-mir-495      | 2.42    | 1q32.31            |
| **Down-regulated** |       |                     |
| hsa-let-7a-1     | 0.83    | 9q22.32            |
| hsa-let-7a-2     | 0.83    | 11q24.1            |
| hsa-let-7a-3     | 0.83    | 22q13.31           |
| hsa-mir-10a      | 0.77    | 11q21.32           |
| hsa-mir-15b      | 0.73    | 3q25.33            |
| hsa-mir-191      | 0.68    | 3p21.31            |
| hsa-mir-21       | 0.76    | 17q23.2            |

a. In the color reversal experiment, two lists of differentially expressed miRNAs from the two reverse labeled arrays are merged into one list
b. A total of 328 human miRNAs were analyzed by miRNA microarray
c. ±ratio represents the ratio between averaged 5-FU treated sample values (+) and the untreated sample values (-)

Validation of selected differentially expressed miRNAs

Five differentially over-expressed miRNA candidates miR-125b, miR-181a, miR-181b, miR-27a and miR-222 were verified by real-time RT-PCR and Northern blot in 5-FU treated and non-treated pancreatic cancer cells. The results indicated that miR-125b, miR-181a, miR-181b, miR-27a and miR-222 were indeed overexpressed in 5-FU treated PANC-1 and Panc-10.05 cells by both real-time RT-PCR (Figure 1A) and Northern blot analysis (Figure 1B). These results were consistent with what we observed from the miRNA microarray analysis.

Figure 1 Confirmation of miRNA microarray results.
A. Real-time RT-PCR of 5-FU treated (+) and untreated (-) pancreatic cancer cells. The 5S rRNA was used as an internal control.
B. Northern blot of 5-FU treated (+) and untreated (-) pancreatic cancer cells. The U6 RNA was used as a loading control.

Inhibition of cell proliferation of miR-125b

In order to evaluate the functions of miRNAs correlated with 5-FU treatment, miRNA precursors were introduced into the cells and the cell proliferation was examined. Transient transfection was performed to determine the minimum concentration of the precursor molecules of selected miRNA to reduce cell toxicity and nonspecific effects. Real-time RT-PCR results showed that the minimum concentration of miR-125b precursor was 2.5nM for both PANC-1 and Panc-10.05 (Figure 2). We also compared the inhibition of the cell growth rate between the minimum (2.5nM) and maximum (80nM) concentration of the miRNA precursor and found no significant difference (at P<0.05, Data not shown). Therefore, the minimum concentration of miR-125b precursor was used for the following experiments.

MTT assay of transient transfection with the minimum concentration of miRNA precursors showed that miR-125b inhibited cell proliferation in both PANC-1 cells (50%) and Panc-10.05 cells (75%) (Figure 2 & 3). But it did not achieve the same inhibition effects as 5-FU treatment.

Figure 2 Optimization experiment for transient transfection of miR-125b. The final concentration of miR-125b was 2.5nM for PANC-1 and Panc-10.05.

Figure 3 MTT assay for miR-125b transient transfection. miR-125b inhibited PANC-1 cell growth and proliferation individually compared with controls. PANC-1: parental cells; panc-10.05: parental cells; liposome: parental cells with Lipofectamine 2000 only.

Selection of positive miR-125b stable transfected clones

A single-stranded DNA oligos for miR-125b (Table 2) was designed and synthesized to construct the expression plasmids. After the expression plasmid contain the desired miRNA was constructed, the sequence was verified and confirmed. Sequencing results were analyzed using the program SeqManTM of DNAStar software (DNASTar, Inc.). Pancreatic cancer cell lines PANC-1 and Panc-10.05 were stably transfected with either the expression plasmid or the control vector using LipofectamineTM 2000. After blasticidin (3μg/ml, Invitrogen, Carlsbad, CA) screening, the stable clones from PANC-1 were identified by real-time RT-PCR and Northern blot analysis (Figure 4). We screened 30 clones from each stable transfection experiment and 4 positive clones were selected for the further characterization. We also tried different transfection reagents (LipofectamineTM 2000 and LipofectamineTM LTX) and different concentrations of blasticidin (0.5μg/ml, 1.5μg/ml and 3μg/ml respectively), but there were no stable clones obtained from Panc-10.05 cell transfection. It may be due to its sensitivity to blasticidin.
Up-regulation of microRNA-125b induced by 5-fluorouracil (5-FU) treatment inhibits cell growth and proliferation in pancreatic cancer cells

Table 2 DNA oligo sequences utilized to construct the miR-125b expression plasmids

| Top strand oligo  | 5'-TGCTGTCCCTGAGACCCTAACTTGTGGTTTTGGCCACTGACTGACCACAAGTTGGTCTCAGGGGA-3' |
|--------------------|----------------------------------------------------------------------------------|
| Bottom strand oligo| 5'-CCCTGTCCCTGAGACCAACTTGTGGTCAGTCAGTGGCCAAAACCACAAGTTAGGGTCTCAGGGAC-3' |

Figure 4 Positive clones screening by real-time PCR and Northern blot.
A. Real-time RT-PCR for positive clones screening using mirVanaTM qRT-PCR miRNA Detection Kit. The SS rRNA was used as an internal control.
B. Northern blot for positive clones screening. The SS rRNA was visualized with ethidium bromide and used as a loading control.

Characteristics of miR-125b stable transfected clones

In order to determine which positive clone had the same characteristics as the 5-FU treated cells, cell growth and proliferation rate of stable clones with miR-125b were tested using MTT assay and Clonogenecity assay. Results shown in Figure 5 & 6 indicated different characteristics of each stable transfected clone. In miR-125b stable transfected clones, only clones 5 and 14 showed a significantly inhibition of cell growth and proliferation rate compared with the control vector clones and PANC-1 parent cells under normal culture conditions (Figure 5B & 6B). From these results, we selected clones 5 & 14 which have repressed growth rate similar to the 5-FU treated cells and precursor molecules transfected cells.

Figure 5 MTT assay of miR-125b, -27a and -222 stable transfectants.
A. No significant difference between the parent cell and miR-vector transfectants 1, 2 and 4.
B. miR-125b transfectants 5 and 14 inhibited cell growth and proliferation compared with controls. miR-vector clone 1, clone 2 and clone 4: transfectants with empty vector; PANC-1: parental cells.

Figure 6 Clonogenecity assay of miR-125b stable transfectants.
A. No significant difference between the parent cell and miR-vector transfectants clone 1, clone 2 and clone 4; **P<0.001.
B. n.s.d., no significant difference. miR-vector clone 1, clone 2 and clone 4: transfectants with empty vector; PANC-1: parental cells.

Inhibition of cell proliferation can be the consequence of cell cycle arrest. Therefore, flow cytometry was performed to determine the alteration of cell cycle. As shown in Figure 7, miR-125b stable transfected clones 5 and 14 showed G2/M phase arrest compared with the control vector clones, while no apoptosis was detected in the stable clones. To identify the potential protein targets of the microRNAs of interest, 2D DIGE and RT-PCR array were performed.

Figure 7 Cell cycle analysis by flow cytometry. miR-125b transfectants 5, 14 and 24 caused G2/M-phase arrest compared with miR-vector transfectants 1, 2 and 4.

Potential protein targets for miR-125b

To explore the potential protein targets of miR-125b, the human apoptosis RT-PCR array is used due to miR-125b inhibits cell growth and proliferation. There were two genes appeared to be down regulated more than 2 folds in miR-125b clones 5and 14 with 2 folds differences when compared with the parent cell line. Western blot analysis was followed to confirm the protein expression of BIRC1 and IGF1R. Both BIRC1 and IGF1R expression were down-regulated in miR-125b clones 5 and 14 and similar to 5-FU treated cells (Figure 8).
Up-regulation of miRNA-125b induced by 5-fluorouracil (5-FU) treatment inhibits cell growth and proliferation in pancreatic cancer cells

Discussion

Compared with the untreated cells, twenty-four up regulated miRNAs and seven down-regulated miRNAs were identified in 5-FU treated cells. Among them, 8 miRNAs (miR-125b, miR-181a, miR-181b, miR-181d, miR-27a, miR-222, miR-30a-5pre and miR-495) showed the most significant up regulation in 5-FU treated group, while other 6 miRNAs were down regulated compared with the untreated group, including miR-15b and miR-21. It has been suggested that miR-21 might play an important role in preventing apoptosis and has been shown to be up regulated in different cancers, pancreatic neuroendocrine tumors included. Moreover, it has been reported that miR-21 was overexpressed in pancreatic cancer and its strong expression predicted limited survival in patients with node-negative disease. If miR-21 is truly involved in the 5-FU regulation, it should be down regulated according to the effect on growth inhibition by 5-FU. We indeed found that miR-21 was down regulated in our studies after 5-FU treatment.

For the up regulated miRNAs, miR-125b is one of the most significantly miRNAs which possibly involve in 5-FU metabolism pathway based on its negative effects on proliferation in different cancers. MiR-125b negatively regulated proliferation in oral squamous cell carcinoma cells. Downregulation of miR-125b expression was found in OSCC, breast cancer and prostate cancer. But in pancreatic cancer, the differential expression of miR-125b is controversial. Volinia et al. reported that the majority of miRNAs were increased in the tumor compared to normal pancreas, including miR-125b. Bloomston et al. also showed that miR-125b was found to be overexpressed in pancreatic cancer compared with normal pancreatic tissue, which was also overexpressed in chronic pancreatitis. The miR-125b expression affected in both diseased tissues is more likely to reflect the desmoplasic reaction of tumor rather than changes specific to PDAC. However, the studies of Lu et al showed miR-125b was decreased in pancreatic cancer compared with normal pancreatic tissues, but little is known about its function in pancreatic cancer. To define how miR-125b affects the pancreatic cell proliferation, the human pancreatic cell lines PANC-1 and Panc-10.05 cells were transfected with Pre-miRTM miRNA precursor molecules of miR-125b, and the results showed that it inhibited cell proliferation in both cell lines. But the inhibition is not the same dramatic as that of 5-FU treated cells, suggesting that there are other miRNAs induced by 5-FU involving in this process. To understand the role of miR-125b, its stable transfected clones were established in PANC-1 cell line. The stable clones (5 and 14) transfected with miR-125b plasmids both showed decreased cell growth and proliferation (about 68% and 87% inhibition for colony formation) which matched with the 5-FU treated cells and precursor molecules transfected cells. But there was no change of cell proliferation in another stable clone 24 which had the highest expression level of miR-125b, suggesting its nonspecific effect. Our results were supported by the previous studies showing over expressing miR-125b, which could inhibit cell proliferation in OSCC, bladder cancer, thyroid cancer and hepatocellular carcinoma. In pancreatic cancer, our results are similar to the findings reported by Lu et al.miR-125b was included in a general downregulation of miRNAs associated with differentiation in tumors compared with normal tissues. Recent studies showed that miR-125b could promote neuronal differentiation in human cells. In the present studies, exogenous miR-125b inhibition of tumor growth may be partly through restoring differentiation capabilities of cancer cells. Further testing whether there are dysregulated genes associated with differentiation in the above tumor will help us better understand the role of miR-125b in the process of recovery of cancer differentiation.

Inhibition of cell proliferation can be the consequence of cell cycle arrest or apoptosis, flow cytometry assay was performed. As shown in Figure 7, miR-125b stable transfected clones 5 and 14 showed G2/M phase arrest compared with the control vector, while no apoptosis was detected in the stable clones. It seems that clone 14 has a higher cell growth inhibition (Clonogenecity assay, 87% versus 68%) accompanying higher percentage G2/M phase arrest (50.35% versus 30.14%) than clone 5. To probe the molecular mechanisms involved in the tumor growth inhibition by miR-125b, human apoptosis RT-PCR array was performed. Two potential protein targets BIRC1 and IGF1R with more than 2-fold of downregulation was identified and confirmation by Western blot. Blotting results (Figure 8) showed that the protein level of BIRC1 and IGF1R was dramatically decreased in 5-FU treated cells and miR-125b transfected clones 5 and 14 compared with the vector controls and the parental. However, no evident decrease of expression IGF1R in clone 24 which has no inhibition effect on cells (data not shown). The IGF-IR has been implicated in promoting oncogenic transformation, growth, and survival of cancer cells. And it is one of the growth factor receptors known to affect the G2/M transition and to be overexpressed in pancreatic cancer. Reduction of IGF-IR was followed by G2/M phase arrest and colony formation inhibition in the present study. Our finding was supported by the hypothesis that the autocrine interaction between the IGF-1R and its ligand regulates cell proliferation of pancreatic carcinoma cells. In experimental studies, inhibition of IGF-IR substantially reduced pancreatic cancer growth and angiogenesis. EM164, an Anti-Insulin-like Growth Factor I Receptor Antibody caused regression of established BxPC-3 human pancreatic tumor xenograft in SCID mice. Therefore, miR-125b-induced downregulation of IGF1-R may be partly responsible for the observed inhibition of cell proliferation in PANC-1 cells. IGF signaling through the IGF-IR may be an important factor in tumor cell drug resistance. Furthermore, inhibition of IGF-IR with antibodies or small-molecule kinase inhibitors has been found to enhance the cytotoxic effects of a number conventional chemotherapeutic agents, 5-FU included, both in vivo and in vitro. Increased expression IGF1-R by over expressing miR-125b may sensitized pancreatic cancer cells to 5-FU which needs further studies. It is also important to determine whether miR-125b can directly repress the expression of IGF1-R.
BIRC1, also named Neuronal apoptosis inhibitory protein (NAIP), which is a member of the IAPs, is expressed in mammalian cells and inhibits the apoptosis induced by a variety of signals. NAIP has been linked to the inherited disease, spinal muscular atrophy (SMA). NAIP may be involved in the mechanisms of resistance of tumor cells to various chemotherapeutic agents. It has been reported NAIP is overexpressed in breast cancer patients with unfavorable clinical features such as stage and tumor size, suggesting that NAIP would play a role in the disease manifestation. In colorectal cancer BIRC1 transcript that was more abundant in tumors than in non-neoplastic tissues appeared to reflect important events for colon carcinogenesis. Our results showed that BIRC1 was down-regulated in 5-FU treated cells and miR-125b stable transfected clones 5 and 14, indicating reduction of BIRC1 might contribute to the inhibition of apoptosis of pancreatic cancer cells. However, we didn’t detect the apoptosis in miR-125b stable transfected cells. Other methods used to test the early apoptosis of cells may be the better choice. Or BIRC1 may have an unidentified role in cell proliferation.

It has been found that miRNA genes are frequently located in chromosomal regions characterized by non-random aberrations in human cancer, suggesting that resident miRNA expression might be affected by these genetic abnormalities. MiR-125b, which inhibited pancreatic tumor growth in the present studies, is located at chromosome 1q23-24, which is one of the region’s most frequently deleted in breast, ovarian, and lung tumors. Loss of 1q12–24.1 and 22q13.31 were also associated with these more advanced tumor cases in endocrine pancreatic tumors. Thus, the miR-125b might be an important candidate for this role.

Summary
In summary, our findings indicated the expression of miR-125b induced by 5-FU treatment, may inhibit tumor growth in part through down-regulation of the expression of IGFR1, suggesting a novel strategy for anticancer therapy.

Acknowledgements
None.

Conflict of interest
The author declares no conflict of interest.

References
1. Oettle H, Reiss H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer. 2002;95(4 Suppl):912–922.
2. Berlin JD, Rothenberg ML. Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep. 2003;5(3):219–226.
3. Martin MM, Lee EJ, Buckenheimer JA, et al. MicroRNA–155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem. 2006;281(27):18277–18284.
4. Alvarez–Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132(21):4653–4662.
5. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–355.
6. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistrionic microRNA cluster, miR–17–92, is over expressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65(21):9628–9632.
7. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let–7 microRNA family. Cell. 2005;120(5):635–647.
8. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down–regulation of micro– RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–15529.
9. Bloomston M, Frankel WL, Petrozza F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901–1908.
10. Feber A, Xi L, Luketch JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 2008;135(2):255–260.
11. Dilhovf M, Liu J, Frankel W, et al. MicroRNA–21 is over expressed in pancreatic cancer and a potential predictor of survival. J Gastroint Surg. 2008;12(12):2171–2176.
12. Henson BJ, Bhattacharjee S, O’Dee DM, et al. Decreased expression of miR–125b and miR–100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer. 2009;48(7):569–582.
13. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–7070.
14. Ozen M, Creighton CJ, Ozdemir M, et al. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008;27(12):1788–1793.
15. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257–2261.
16. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
17. Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125(2):345–352.
18. Le MT, Xie H, Zhou B, et al. MicroRNA–125b Promotes Neuronal Differentiation in Human Cells by Repressing Multiple Targets. Mol Cell Biol. 2006;29(19):5309–5315.
19. Baserga R, Hongo A, Rubini M, et al. The IGF–I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997;1332(3):F105–F116.
20. Blakesley VA, Stannard BS, Kalebic T, et al. Role of the IGF–I receptor in mutagenesis and tumor promotion. J Endocrinol. 1997;152(3):339–344.
21. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulin like growth factor I receptor promotes ligand–dependent neoplastic transformation. Mol Cell Biol. 1990;10(2):464–473.
22. Bergmann U, Funatomi H, Yokoyama M, et al. Insulin–like growth factor I receptor antibody that is a potent inhibitor of cancer cell growth. Differentiation in Human Cells by Repressing Multiple Targets. Mol Cell Biol. 1997;1332(3):F105–F126.
23. Blakesley V A, Stannard BS, Kalebic T, et al. Role of the IGF–I receptor in mutagenesis and tumor promotion. J Endocrinol. 1997;152(3):339–344.
24. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulin like growth factor I receptor promotes ligand–dependent neoplastic transformation. Mol Cell Biol. 1990;10(2):464–473.
25. Bergmann U, Funatomi H, Yokoyama M, et al. Insulin–like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995;55(10):2007–2011.
26. Stoeltzing O, Liu W, Reinmuth N, et al. Regulation of hypoxia–inducible factor–1alpha, vascular endothelial growth factor, and angiogenesis by an insulin–like growth factor–I receptor autocrine loop in human pancreatic cancer. Am J Pathol. 2003;163(3):1001–1011.
27. Maloney EK, McLaughlin JL, Dagdigen NE, et al. An anti–insulin–like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003;63(16):5073–5083.
28. Gooch JL, Van Den Berg CL, Yee D. Insulin–like growth factor (IGF)–I rescues breast cancer cells from chemotheraphy–induced cell death—proliferative and anti-apoptotic effects. Breast Cancer Res Treat. 1999;56(1):1–10.

Citation: Liu Y, Liu Z, Xia Z, et al. Up-regulation of microRNA-125b induced by 5-fluorouracil (5-FU) treatment inhibits cell growth and proliferation in pancreatic cancer cells. MOJ Cell Sci Rep. 2016;3(1):30–37. DOI: 10.15406/mojcsr.2016.03.00048
Up-regulation of microRNA-125b induced by 5-fluorouracil (5-FU) treatment inhibits cell growth and proliferation in pancreatic cancer cells

26. Tao Y, Pinzi V, Bourhis J, et al. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2007;4(10):591–602.

27. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379(6563):349–353.

28. Choi J, Hwang YK, Choi YJ, et al. Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean Med Sci. 2007;22 Suppl:S17–S23.

29. Bianchini M, Levy E, Zucchini C, et al. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol. 2006;29(1):83–94.

30. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004.

31. Negrini M, Rasio D, Hampton GM, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res. 1995;55(14):3003–3007.

32. Rasio D, Negrini M, Manenti G, et al. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. Cancer Res. 1995;55(18):3988–3991.

33. Jonkers YM, Claessen SM, Feuth T, et al. Novel candidate tumour suppressor gene loci on chromosomes 11q23–24 and 22q13 involved in human insulinoma tumourigenesis. J Pathol. 2006;210(4):450–458.